Seagen Debuts In EU With Tukysa Launch & Sees UK As 'Key' Future Market
Pricing And Reimbursement Talks Getting Under Way
Tuomo Pätsi of US biotech firm Seagen discusses plans for the rollout of Tukysa in Europe, how it successfully used a new mechanism for approval in Great Britain, and why the UK will be a go-to market for future innovative drug filings.
